EXEL – exelixis, inc. (US:NASDAQ)

News

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Stephens. They set an "equal weight" rating and a $23.00 price target on the stock.
Exelixis files patent suit against India's Cipla over Cabometyx generics [Seeking Alpha]
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Exelixis (EXEL) International Revenue Performance Explored [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com